Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

    Basic Details
    Date
    Wednesday, November 1, 2017
    Type
    Publication
    Medical Product
    anti-diabetic agent (ADA)
    dipeptidyl peptidase-4 (DPP-4) inhibitor
    glimepiride
    glipizide
    glyburide
    hypoglycemic drug
    long-acting insulin
    pioglitazone
    saxagliptin
    sitagliptin
    sulfonylurea
    thiazolidinedione
    Health Outcome(s)
    acute myocardial infarction (AMI)
    Description

    The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. This article prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI). The authors did not find a higher AMI risk in saxagliptin users compared with users of other selected antihyperglycemic agents during the first 5 years after U.S. Food and Drug Administration approval of the drug.

    Author(s)

    Sengwee Toh ScD; Marsha E. Reichman PhD; David J. Graham MD, MPH; Christian Hampp PhD; Rongmei Zhang PhD; Melissa G. Butler PharmD PhD; Aarthi Iyer MPH; Malcolm Rucker MS; Madelyn Pimentel BA; Jack Hamilton; Samuel Lendle; Bruce H. Fireman MA; the Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group